Health Care

Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back

Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back

Traws Pharma's Oral COVID Drug Shows Comparable Results To Paxlovid

Traws Pharma's Oral COVID Drug Shows Comparable Results To Paxlovid

FDA Approves GSK's Drug, Targets Severe Asthma With Two Doses Per Year

FDA Approves GSK's Drug, Targets Severe Asthma With Two Doses Per Year

Traws Pharma's Oral COVID Drug Shows Comparable Results To Paxlovid

Traws Pharma's Oral COVID Drug Shows Comparable Results To Paxlovid

FDA Approves GSK's Drug, Targets Severe Asthma With Two Doses Per Year

FDA Approves GSK's Drug, Targets Severe Asthma With Two Doses Per Year

Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing

Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing

Why Is Monte Rosa Stock Trading Higher Today?

Why Is Monte Rosa Stock Trading Higher Today?

Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing

Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing

Why Is Monte Rosa Stock Trading Higher Today?

Why Is Monte Rosa Stock Trading Higher Today?

Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion

Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion

RadNet Stock Hit By Short Seller Report, Questions AI Hype, Growth Claims

RadNet Stock Hit By Short Seller Report, Questions AI Hype, Growth Claims

Health Care Recent News

Cigna Offers Cleaner Growth Than Other Health Insurers, Says Analyst

Cigna Offers Cleaner Growth Than Other Health Insurers, Says Analyst

BofA outlines risks and upside for managed care stocks, favoring Cigna and Alignment while flagging Medicare and Medicaid uncertainty.

Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel

Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel

Soligenix reports positive Phase 2a extension results for SGX302 gel in psoriasis, showing improved skin scores and strong tolerability.

Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?

Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?

Processa Pharmaceuticals' stock jumps after Phase 2 data show higher capecitabine exposure without added toxicity in metastatic breast cancer patients.

Merck's Keytruda-Padcev Combo Boosts Survival In Pivotal Bladder Cancer Trial

Merck's Keytruda-Padcev Combo Boosts Survival In Pivotal Bladder Cancer Trial

Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder cancer trial.

Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Vistagen shares plunge after its Phase 3 fasedienol trial for social anxiety failed to meet the primary endpoint, despite favorable safety data.

FDA Approves Brain Tumor Warning For Pfizer's Depo-Provera Amid Lawsuit

FDA Approves Brain Tumor Warning For Pfizer's Depo-Provera Amid Lawsuit

FDA approves a new Depo-Provera warning on meningioma risk as Pfizer faces lawsuits alleging delayed disclosure of brain tumor concerns.

Why Did Agape ATP Corp (ATPC) Stock Surge 44% After Hours?

Why Did Agape ATP Corp (ATPC) Stock Surge 44% After Hours?

Agape ATP shares jumped 43.89% after hours following a statement addressing recent stock volatility.

ImmunityBio Reports Strong Long-Term Survival Data For Anktiva In Bladder Cancer Study

ImmunityBio Reports Strong Long-Term Survival Data For Anktiva In Bladder Cancer Study

ImmunityBio says Anktiva plus BCG showed durable survival and bladder preservation at 36 months in BCG-unresponsive bladder cancer patients.

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday

Cellectis shares fell after Allogene cited a favorable arbitration ruling confirming control of cema-cel and outlining key CAR-T milestones.

AstraZeneca Gets FDA Nod For Breast Cancer Drug, EU Clearance For Lupus Pen

AstraZeneca Gets FDA Nod For Breast Cancer Drug, EU Clearance For Lupus Pen

FDA approves AstraZeneca and Daiichi's Enhertu combo for first-line HER2-positive breast cancer, while the EU clears Saphnelo self-injection for lupus.

Radiation Therapy-Focused Accuray Details Workforce Reduction, Outsourcing In Major Transformation Push

Radiation Therapy-Focused Accuray Details Workforce Reduction, Outsourcing In Major Transformation Push

Accuray outlines a restructuring plan aimed at $25 million in annual profit gains through cost cuts, workforce reduction and operational realignment.

What's Going On With uniQure Stock On Tuesday?

What's Going On With uniQure Stock On Tuesday?

uniQure shares slid nearly 31% in a month as the FDA raised concerns over whether AMT-130 Phase 1/2 data can support approval.

Pfizer Sees Slower 2026 Growth Despite Pipeline Push, Cost Cuts

Pfizer Sees Slower 2026 Growth Despite Pipeline Push, Cost Cuts

Pfizer previews 2026 guidance with earnings below consensus, softer sales outlook, COVID decline and LOE headwinds offset by pipeline growth.